Literature DB >> 1850611

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

J A Henry1, N H Piggott, U K Mallick, S Nicholson, J R Farndon, B R Westley, F E May.   

Abstract

Expression of the oestrogen-regulated pNR-2/pS2 protein has been studied in paraffin sections of a series of 172 primary breast cancers using an immunohistochemical technique. Positive staining of tumour cells was found in 117 tumours (68%): most of these tumours contained only a small proportion of positive cells. pNR-2 immunohistochemical staining correlated positively and significantly with the presence of oestrogen receptor. Mean percentages of pNR-2 positive cells were lower in tumours from postmenopausal women. Smaller, better differentiated tumours were significantly more likely to stain positively for pNR-2. The percentages of pNR-2 positive tumour cells in primary tumours and synchronously excised lymph node metastases were very similar. pNR-2 expression showed an unexpected positive association with lymph node metastasis. We were unable to find any significant association between pNR-2 immunohistochemical staining and either time to relapse or overall survival. There was a significant association between pNR-2 expression in primary tumours and response to endocrine therapy on relapse: positive pNR-2 immunohistochemical staining in primary tumours is predictive of response to hormonal therapy on relapse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850611      PMCID: PMC1972364          DOI: 10.1038/bjc.1991.141

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Oestrogen-responsive human breast cancer in long term tissue culture.

Authors:  M E Lippman; G Bolan
Journal:  Nature       Date:  1975-08-14       Impact factor: 49.962

2.  Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coli.

Authors:  J F Prud'homme; A Jolivet; M F Pichon; J F Savouret; E Milgrom
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

3.  Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma.

Authors:  S Soomro; S Shousha
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

Review 4.  Tamoxifen in advanced breast cancer.

Authors:  H Mouridsen; T Palshof; J Patterson; L Battersby
Journal:  Cancer Treat Rev       Date:  1978-09       Impact factor: 12.111

5.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

6.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

7.  Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer.

Authors:  R A McClelland; P Finlay; K J Walker; D Nicholson; J F Robertson; R W Blamey; R I Nicholson
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues.

Authors:  N A Wright; R Poulsom; G W Stamp; P A Hall; R E Jeffery; J M Longcroft; M C Rio; C Tomasetto; P Chambon
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

9.  Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors.

Authors:  W J King; E R DeSombre; E V Jensen; G L Greene
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

10.  Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.

Authors:  J A Henry; S Nicholson; C Hennessy; T W Lennard; F E May; B R Westley
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

View more
  35 in total

1.  The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach.

Authors:  J L Newton; A Allen; B R Westley; F E May
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 2.  Trefoil peptides.

Authors:  W M Wong; R Poulsom; N A Wright
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

3.  High expression of the trefoil protein TFF1 in interval breast cancers.

Authors:  M Crosier; D Scott; R G Wilson; C D Griffiths; F E May; B R Westley
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Expression of the pS2 gene in breast tissues assessed by pS2-mRNA analysis and pS2-protein radioimmunoassay.

Authors:  E Hähnel; P Robbins; J Harvey; G Sterrett; R Hähnel
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Treating elderly patients with breast cancer.

Authors:  K Dookeran; A Stotter; R Windle; R Walker
Journal:  BMJ       Date:  1992-05-23

6.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

7.  Hyperplastic polyps: a cell lineage which both synthesizes and secretes trefoil-peptides and has phenotypic similarity with the ulcer-associated cell lineage.

Authors:  A M Hanby; R Poulsom; S Singh; J Jankowski; D Hopwood; G Elia; L Rogers; K Patel; N A Wright
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

8.  Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

Authors:  I Soubeyran; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Expression of pS2 protein in breast cancer.

Authors:  G Crombach; A Ingenhorst; U J Göhring; A Scharl; W Neuhaus; V Möbus; H J Schaeffer
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

Review 10.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.